M6 in the prevention of peripheral neuropathy caused by chemotherapy: a study

04 April 2022 - Research -
Share

NEUROLASER is the name of the recent pilot study carried out by a team of researchers from the medical faculty of Hasselt University in collaboration with doctors from the departments of Oncology and Neurology of the Jessa Hospital (Hasselt, Belgium).

The clinical trial investigated the efficacy and safety of photobiomodulation therapy (PBMT) delivered by laser source (M6) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer.

The team, led by Dr. Robijns, involved 32 patients in the study, of which 16 underwent PBMT while 16 were given placebo treatment.

The data collected revealed promising results in terms of prevention. Symptoms such as numbness of the hands and feet worsened significantly in the control group, while they remained constant in the group treated with PMB. The quality of life in treated patients also improved compared to the control patients. All the laser therapy treatments were shown to be safe and free from undesirable effects.

To confirm the applicability and effectiveness of laser therapy in the prevention of peripheral neuropathies induced by chemotherapy, further studies are required, which will contribute to increasing the number of cases. However, this preliminary study provides encouraging results on the possibility of applying the M6 system in supportive therapies for cancer patients, as already highlighted by previous experiences related to the treatment of radiodermatitis.

Testo a Destra
Immagine 30%/Testo 60%
Supportive Care in Cancer - Springer

“The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial)”
Supportive Care Cancer, Mar 21;1-9, 2022

READ MORE

You might also be interested in ...

See all articles

blog - 15/09/2021
The results of this study allow defining the neuroprotective mechanisms of the laser therapy carried out by MLS-MiS, to highlight its anti-inflammatory effect and to underline its potential benefit...
M8 laser treatment for pain due to COVID-19
blog - 09/04/2021
The results actually showed that patients undergoing MLS® Laser Therapy had a rapid recovery
Lasers in Surgery and Medicine - Journal
Research
J. Robijns, S. Censabella, S. Claes, L. Pannekoeke, L. Bussé, D. Colson, I. Kaminski, P. Bulens, A. Maes, L. Noé, M. Brosens, A. Timmermans, I. Lambrichts, V. Somers, J. Mebis Lasers in Surgery and...
ASA Partners Meeting 2024
News - 21/03/2024
Four days of full immersion in the world of ASA to focus on the new devices - M-Hi and HIRO – and to analyse the biological effects of Hilterapia®.
ASAlaser @ FIF Milano 2024
News - 19/03/2024
Not only top-of-the-line devices, including the new HIRO and M-Hi as well as Magneto Qs and M8, but also three workshops aimed at highlighting the strengths of its therapies.
ASA tema @ ArabHealth 2024
News - 15/02/2024
In order to provide maximum visibility and the best dissemination of the strengths of its Therapeutic Solutions, the company preceded its attendance at the fair (Dubai, 29th January – 1st February)...